Services

Optimum Dosing Strategies’s ID – ODS design allows integration with a variety of third-party systems, giving health care practitioners vital access to the data they need at the point of care. Click here to contact us for further details about integrating ID – ODS into the workflow with your institutions electronic medical record.

Recharge

2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction?  2012, Antimicrobial Agents and Chemotherapy, 56: 4560

More

ID-ODS: Bayesian dose optimization application…

ID-ODS: Bayesian dose optimization application…

Join the growing number of community of ID-ODS users worldwide!

More

See recent publication on ID – ODS!

See recent publication on ID – ODS!

A review article published in May, 2020 in the journal Frontiers in Pharmacology indicates that ID-ODS is in a leading position versus its comparators for versatility, complexity and readiness for easy integration into clinical practice!.

More

ID – ODS supports AUC based Vancomycin dosing!

ID – ODS supports AUC based Vancomycin dosing!

ID – ODS, our state of the art system for Bayesian analysis and Monte Carlo Simulation, is featuring AUC/MIC ratio based dose optimization for Vancomycin and the Aminoglycosides!

More

Manuscripts and Letters

2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction?  2012, Antimicrobial Agents and Chemotherapy, 56: 4560

More

IDSA

2014 – Barry P.; Deck D.; Farkas A.; Pharmacokinetic modeling of linezolid dosing regimens for multidrug resistant tuberculosis

2013 – Farkas A, Rowin K; Pharmacodynamics of doripenem in critically ill patients: does race matter

More

ACCP

2012- Sussman R, Farkas A, Lee A, Evaluation of pharmacist managed vancomycin therapy compared to physician managed dosing in establishing timely and therapeutic vancomycin serum concentrations at a community hospital

2012 – Farkas A, Keren A, Hoffman C; Novel method to maximize levofloxacin pharmacodynamics for the treatment of systemic gram negative infections based on the population distribution of patient demographics at a community hospital

More

ECCMID

2014 – Farkas A, Daroczi G, Roberts J, Population Probability of Target Attainment of Colistin at Different Levels of Renal Function Against Pseudomonas aeruginosa and Acinetobacter baumanii in Europe

2014 – Farkas A, Daroczi G, Roberts J, Usage statistics of Individually Designed Optimum Dosing Strategies, a multi-model based online application to individualize antibiotic dosing in critically ill patients

More

ICAAC

2014 – Farkas A.; Saju S.; Gould P.; Kuriyilel J.; Villasurda P.; Roberts J.; Comparative evaluation of the performance of a population equation and two Bayesian methods to predict future Vancomycin concentrations .

2014 – Farkas A.; Villasurda P.; Feldfogel H.; Afroz S.; Evaluation Of The Safety And Efficacy Of Low Versus High Vancomycin Trough Levels For The Treatment Of Conditions Caused By Methicillin-Resistant Staphylococcus Aureus

More